Kazia Therapeutics Ltd · NASDAQ:KZIA
Kazia Therapeutics — Gold Coast Investment Showcase 2018
20 slides from Kazia Therapeutics's conference presentation, Jun 21, 2018
Slide 1: An emerging oncology developer with two clinical-stage programs
An emerging oncology developer with two clinical-stage programs Gold Coast Investment Showcase Surfers Paradise 20 & 21 June 2018
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation contains “forward-looking statements” within the meaning of the “safe-harbor” provisions of the Private Securities Litigation Reform Act of 1995. Such statements involve known and unknown risks, uncertainties and other factors that could cause the actual
Slide 3: Investment Highlights
Investment Highlights 1 Cancer-focused biotech with two distinct therapies in clinical trials - GDC-0084 entering phase II trial for brain cancer - Cantrixil currently in phase I trial for ovarian cancer 2 Well-differentiated assets, with lead program licensed from Genentech - GDC-0084: targets a cr
Slide 4: Kazia is focused on development of high-potential novel therapies for poorly-served cancers
Kazia is focused on development of high-potential novel therapies for poorly-served cancers Partner with big pharma for late-stage development to bring to market Bring in under-valued assets from other pharmaceutical companies Conduct focused clinical trials Identify optimal patient groups Understan
Slide 5: A strong team brings international experience in big pharma and early-stage biotech
A strong team brings international experience in big pharma and early-stage biotech Board Scientific Advisory Board Iain Ross Chairman Executive and Board roles in pharma and small biotech Bryce Carmine Deputy Chairman 36 years executive experience in Eli Lilly Steven Coffey Non-Executive Director C
Slide 6: Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 35 million
Kazia is listed on ASX and NASDAQ, with a market cap of ~AU$ 35 million Market Capitalisation AU$ 35 million Shares on Issue 48.3 million (35% US, 65% Australia) Current Assets ~AU$ 14.8 million Listing ASX: KZA NASDAQ: KZIA (1:10 ratio) Share Price (AU$) Outstanding Options / Warrants ~6 million Av
Slide 7: Our efforts are attracting increasing attention from media and the investment community
Our efforts are attracting increasing attention from media and the investment community
Slide 8: Two clinical programs, with value-driving inflection points during 2018
Two clinical programs, with value-driving inflection points providing impactful newsflow during 2018 GDC-0084 Glioblastoma Multiforme (GBM) Cantrixil Ovarian Cancer Brain-penetrant PI3K inhibitor, developed to completion of phase I by Genentech Third-generation benzopyran, developed from Australian
Slide 9: Cantrixil Phase I Ovarian Cancer
Cantrixil Phase I Ovarian Cancer
Slide 10: Ovarian cancer remains a disease of high unmet medical need
Ovarian cancer remains a disease of high unmet medical need Cause of death for 1 in 100 women 10% of cases are primarily genetic in origin Lung 14 million cancer cases per annum Breast Colon Prostate Stomach >60% of patients have disease spread at diagnosis 80% of patients are over 50 years of age F
Slide 11: Cantrixil targets cancer stem cells which are often resistant to chemotherapy
Cantrixil has been developed to target ‘cancer stem cells’ which are often resistant to chemotherapy Tumor cancer stem cells daughter cells Chemo-therapy Recurrence Data courtesy of Prof Gil Mor, Yale University Ovarian cancer tumours contain a mixture of different cell types Chemotherapy is not ver
Slide 12: Encouraging signals observed from interim data in phase I study
Encouraging signals observed from interim data in phase I study Part A: Dose Escalation 3 to 42 patients in up to 8 cohorts Seeks to establish maximum tolerated dose and elucidate safety profile Part B: Dose Expansion 12 patients at MTD Seeks to glean efficacy signals Interim Data – 19 June 2018 10
Slide 13: GDC-0084 Phase II Glioblastoma Multiforme
GDC-0084 Phase II Glioblastoma Multiforme
Slide 14: Glioblastoma is the most common and most aggressive form of primary brain cancer
Glioblastoma (GBM) is the most common and most aggressive form of primary brain cancer Lung 14 million cancer cases per annum Breast Colon Prostate Stomach No clear cause or strong risk factors 3-4 months untreated survival 12-15 months average survival with treatment Any age, but most common in 60s
Slide 15: Growing public attention for brain cancer highlights need for new treatment options
Growing public attention for brain cancer highlights need for new treatment options There is increasing recognition of the need to find treatment options for patients diagnosed with GBM Senator John McCain’s diagnosis in July 2017 highlighted glioblastoma and focused attention on the need for new tr
Slide 16: The PI3K class has been validated by approval of a new therapy in September 2017
The PI3K class has been validated by approval of a new therapy in September 2017 Two PI3K inhibitors now successfully brought to market Zydelig (idelalisib) [Gilead] Aliqopa (copanlisib) [Bayer] Neither drug is brain-penetrant, so are unlikely to rival GDC-0084 Demonstrates that PI3K is a validated
Slide 17: Genentech's phase I of GDC-0084 established dosing and showed favourable safety
Genentech’s phase I of GDC-0084 established dosing and showed favourable safety Efficacy Signals Safety Phase I safety trial conducted by Genentech 47 patients enrolled with advanced glioma (grade 3/4); average of three prior lines of therapy Most common adverse events were oral mucositis and hyperg
Slide 18: Other companies focused on the PI3K pathway have been highly-valued in the market
Single asset company with one PI3K inhibitor in phase I human trials US$ 130 million Market Cap One PI3K inhibitor in phase II human trials, one other drug in phase III, and two in animal testing US$ 1.2 billion Market Cap One PI3K inhibitor in phase II human trials Acquired by big pharma in 2011 fo
Slide 19: Investment Highlights
Investment Highlights 1 Cancer-focused biotech with two distinct therapies in clinical trials - GDC-0084 entering phase II trial for brain cancer - Cantrixil currently in phase I trial for ovarian cancer 2 Well-differentiated assets, with lead program licensed from Genentech - GDC-0084: targets a cr
Slide 20: Kazia Therapeutics
KAZIA THERAPEUTICS www.kaziatherapeutics.com info@kaziatherapeutics.com
Kazia Therapeutics — Gold Coast Investment Showcase 2018 on 6ix